肝细胞癌
免疫抑制
髓样
免疫疗法
炎症
生物
医学
癌症研究
先天免疫系统
免疫系统
免疫学
作者
Julie Giraud,Domitille Chalopin,Eloïse Ramel,Thomas Boyer,Atika Zouine,Marie-Alix Derieppe,Nicolas Larmonier,Olivier Adotévi,Brigitte Le Bail,Jean–Frédéric Blanc,Camille Laurent,L. Chiche,Marc Derive,Macha Nikolski,Maya Saleh
出处
期刊:Cell Reports
[Elsevier]
日期:2024-02-01
卷期号:: 113773-113773
被引量:1
标识
DOI:10.1016/j.celrep.2024.113773
摘要
Hepatocellular carcinoma (HCC) is an inflammation-associated cancer arising from viral or non-viral etiologies including steatotic liver diseases (SLDs). Expansion of immunosuppressive myeloid cells is a hallmark of inflammation and cancer, but their heterogeneity in HCC is not fully resolved and might underlie immunotherapy resistance. Here, we present a high-resolution atlas of innate immune cells from patients with HCC that unravels an SLD-associated contexture characterized by influx of inflammatory and immunosuppressive myeloid cells, including a discrete population of THBS1+ regulatory myeloid (Mreg) cells expressing monocyte- and neutrophil-affiliated genes. THBS1+ Mreg cells expand in SLD-associated HCC, populate fibrotic lesions, and are associated with poor prognosis. THBS1+ Mreg cells are CD163+ but distinguished from macrophages by high expression of triggering receptor expressed on myeloid cells 1 (TREM1), which contributes to their immunosuppressive activity and promotes HCC tumor growth in vivo. Our data support myeloid subset-targeted immunotherapies to treat HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI